利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.039 秒)

    Boholmycin antibiotic
    4.
    发明授权
    Boholmycin antibiotic 失效
    博尔霉素抗生素

    公开(公告)号：US4792545A

    公开(公告)日：1988-12-20

    申请号：US817212

    申请日：1986-01-08

    申请人： Kyoichiro Saitoh ,  Mitsuaki Tsunakawa ,  Masataka Konishi ,  Takeo Miyaki

    发明人： Kyoichiro Saitoh ,  Mitsuaki Tsunakawa ,  Masataka Konishi ,  Takeo Miyaki

    IPC分类号： C07H15/234 ,  C12P19/46 ,  A61K31/71 ,  C07H15/20

    CPC分类号： C07H15/234 ,  C12P19/46

    摘要： Boholmycin antibiotic is prepared by fermentation of Streptomyces hygroscopicus H617-25 (ATCC No. 53240) in a nutrient medium preferably comprising glycerol, bacto-liver, cornsteep liquor, ammonium sulfate, sodium chloride and calcium carbonate. The antibiotic and pharmaceutically acceptable salts and hydrates thereof and compositions containing these are effective against Gram-positive, Gram-negative and acid-fast bacteria and against bacterial strains which are resistant to previously known aminoglycoside antibiotics and are useful to treat bacterial infections in mammals.

    摘要翻译： 通过在优选包含甘油，细菌肝，玉米浸液，硫酸铵，氯化钠和碳酸钙的营养培养基中发酵吸水链霉菌H617-25（ATCC No.53240）来制备博尔霉素抗生素。 抗生素及其药学上可接受的盐和水合物以及含有它们的组合物对革兰氏阳性，革兰氏阴性和酸性抗菌细菌和对先前已知的氨基糖苷类抗生素具有抗性的细菌菌株是有效的，并且可用于治疗哺乳动物的细菌感染。

    Antiviral antibiotic BU-3889V
    5.
    发明授权
    Antiviral antibiotic BU-3889V 失效
    抗病毒抗生素BU-3889V

    公开(公告)号：US5098708A

    公开(公告)日：1992-03-24

    申请号：US546463

    申请日：1990-07-06

    申请人： Masataka Konishi ,  Mitsuaki Tsunakawa ,  Osamu Tenmyo ,  Takeo Miyaki ,  Toshikazu Oki

    发明人： Masataka Konishi ,  Mitsuaki Tsunakawa ,  Osamu Tenmyo ,  Takeo Miyaki ,  Toshikazu Oki

    IPC分类号： C12P1/06

    CPC分类号： C12P1/06 ,  Y10S435/822 ,  Y10S435/826

    摘要： Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

    摘要翻译： 公开了通过新型微生物Amycolatopsis orientalis ATCC-53884的BU-3889V生产菌株的发酵生产抗病毒抗生素复合物BU-3889V及其生物活性成分A1，A2，A3，D1，D2和D3。 通过使用离子交换色谱技术分离复合物BU-3889V并将组分分离。 生物活性成分的特征在于其物理化学性质。 已经发现这些产品有效地抑制包括单纯疱疹病毒，人类免疫缺陷病毒（HIV）和流感病毒在内的病毒。

    Antiviral antibiotic BU-3889V
    6.
    发明授权
    Antiviral antibiotic BU-3889V 失效
    抗病毒抗生素BU-3889V

    公开(公告)号：US5286649A

    公开(公告)日：1994-02-15

    申请号：US819543

    申请日：1992-01-10

    申请人： Masataka Konishi ,  Mitsuaki Tsunakawa ,  Osamu Tenmyo ,  Takeo Miyaki ,  Toshikazu Oki

    发明人： Masataka Konishi ,  Mitsuaki Tsunakawa ,  Osamu Tenmyo ,  Takeo Miyaki ,  Toshikazu Oki

    IPC分类号： A61K35/74 ,  A61P31/12 ,  C07G11/00 ,  C12P1/06 ,  C12R1/01 ,  C12N1/20

    CPC分类号： C12P1/06 ,  Y10S435/822

    摘要： Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

    摘要翻译： 公开了通过新型微生物Amycolatopsis orientalis ATCC-53884的BU-3889V生产菌株的发酵生产抗病毒抗生素复合物BU-3889V及其生物活性成分A1，A2，A3，D1，D2和D3。 通过使用离子交换色谱技术分离复合物BU-3889V并将组分分离。 生物活性成分的特征在于其物理化学性质。 已经发现这些产品有效地抑制包括单纯疱疹病毒，人类免疫缺陷病毒（HIV）和流感病毒在内的病毒。

    Process for preparing antiviral antibiotic BU-3889V
    7.
    发明授权
    Process for preparing antiviral antibiotic BU-3889V 失效
    制备抗病毒抗生素BU-3889V的方法

    公开(公告)号：US5124150A

    公开(公告)日：1992-06-23

    申请号：US624029

    申请日：1991-03-11

    申请人： Masataka Konishi ,  Mitsuaki Tsunakawa ,  Osamu Tenmyo ,  Takeo Miyaki ,  Toshikazu Oki

    发明人： Masataka Konishi ,  Mitsuaki Tsunakawa ,  Osamu Tenmyo ,  Takeo Miyaki ,  Toshikazu Oki

    IPC分类号： C12P1/06

    CPC分类号： C12P1/06 ,  Y10S435/822

    摘要： Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

    摘要翻译： 公开了通过新型微生物Amycolatopsis orientalis ATCC-53884的BU-3889V生产菌株的发酵生产抗病毒抗生素复合物BU-3889V及其生物活性成分A1，A2，A3，D1，D2和D3。 通过使用离子交换色谱技术分离复合物BU-3889V并将组分分离。 生物活性成分的特征在于其物理化学性质。 已经发现这些产品有效地抑制包括单纯疱疹病毒，人类免疫缺陷病毒（HIV）和流感病毒在内的病毒。

    Polysubstituted thiazolylpyridine carboxyamide antifungal antibiotic
    9.
    发明授权
    Polysubstituted thiazolylpyridine carboxyamide antifungal antibiotic 失效
    多取代噻唑吡啶羧酰胺抗真菌抗生素

    公开(公告)号：US4956374A

    公开(公告)日：1990-09-11

    申请号：US226016

    申请日：1988-07-29

    申请人： Maki Nishio ,  Shigeyuki Ando ,  Takeo Miyaki ,  Masataka Konishi ,  Toshikazu Oki

    发明人： Maki Nishio ,  Shigeyuki Ando ,  Takeo Miyaki ,  Masataka Konishi ,  Toshikazu Oki

    IPC分类号： C07D417/04 ,  C12P17/16

    CPC分类号： C07D417/04 ,  C12P17/16 ,  C12R1/01

    摘要： Novel antifungal antibiotic compounds have the structural formula ##STR1## A preferred compound where R is 4-hydroxypentyl is denoted BU-3557B.sub.2. A complex of said compounds is produced by fermenting a culture of Sacchrothrix aerocolonigenes strain N806-4 (ATCC 53712). The complex is recovered by adsorption on nonionic porous polymer resin adsorbent and individual component compounds exhibit in vitro activity against fungi and Gram-positive bacteria and BU-3557B.sub.2 demonstrates in vitro antiprotazoal activity. BU-3557B.sub.2 demonstrates in vivo activity against C. albicans vaginal infection and BU-3557A.sub.3 (where R is 1,5-dihydroxy-5,5-dimethylpentyl) demonstrates in vivo activity against C. albicans systemic infection.

    摘要翻译： 新型抗真菌抗生素化合物具有结构式：其中R为4-羟基戊基的优选化合物为BU-3557B2。 通过发酵产气荚膜梭菌菌株N806-4（ATCC 53712）的培养物产生所述化合物的复合物。 通过非离子多孔聚合物树脂吸附剂上的吸附回收复合物，并且各组分化合物表现出对真菌和革兰氏阳性细菌的体外活性，并且BU-3557B2证明体外抗原辅素生物活性。 BU-3557B2证明体内活性针对白色念珠菌阴道感染和BU-3557A3（其中R为1,5-二羟基-5,5-二甲基戊基）表现出对白色念珠菌全身感染的体内活性。